Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — FY2020 Earnings Presentation
23 slides from Abcellera Biologics's earnings presentation, Mar 29, 2021
Slide 1: 2020 Business Update
ellera 2020 BUSINESS UPDATE March 29, 2021
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently av
Slide 3: 2020 Business Update Highlights
2 0 2 0 B U S I N E S S U P D A T E . HIGHL IGHTS Proved tech & ~400K business model clinical trials 90 days after initiation. PATIENTS TREATED Bamlanivimab authorized in 15 countries. 72% INCREASE IN # OF PARTNERSHIPS Strengthened OrthoMabTM and Trianni. competitive $126 million for CMC and advanta
Slide 4: Deep tech, complex integration, at scale
2 0 2 0 B U S I N E S S U P D AT E . TEC HNOLOGY STA C K DEEP TECH, COMPLEX INTEGRATION, AT SCALE. focus on one or a limited number of uniquely integrate proprietary technologies each of these steps
Slide 5: Accelerate discovery. Share in the success.
2 0 2 0 B U S I N E S S U P D A T E . PA RT NERSHIP BU S INESS M OD EL ACCELERATE DISCOVERY. SHARE IN THE SUCCESS. PARTNER Pre-clinical Phase 1 Phase 2 Phase 3 Approval Commercial Sale BIOTECH, PHARMA target mAb ABCELLERA Building a diversified portfolio of milestones & royalties (primary value driv
Slide 6: AI-powered platform built on real-world data
2020 BUSINESS UPDATE. TECHNOLOGY ADVANTAGE AI-POWERED PLATFORM BUILT ON REAL-WORLD DATA. We believe our technology advantage comes from combining three things: 1 2 3 Proprietary technologies Custom software to Artificial intelligence and that can generate massive aggregate, store and powerful comput
Slide 7: Democratize the industry
2020 BUSINESS UPDATE. TECHNOLOGY ADVANTAGE DEMOCRATIZE THE INDUSTRY.
Slide 8: Unlock new targets. Empower partners to move quickly.
2 0 2 0 B U S I N E S S U P D A T E . PA RT NERSHIPS UNLOCK NEW TARGETS. EMPOWER PARTNERS TO MOVE QUICKLY. JAN FEB MAR APR MAY JUN JULY AUG SEP OCT NOV DEC Animal health Undisclosed COVID-19 + Oncology & Animal health Oncology additional indications immunology Ophthalmology
Slide 9: The first COVID-19 antibody treatment to reach the clinic in N. America
2020 BUSINESS UPDATE. COVID-19 PROGRAM THE 1 COVID-19 ANTIBODY TREATMENT ST TO REACH THE CLINIC IN N. AMERICA. DAY 0 From patient sample to human testing in 90 days DAY 90 Sample ~5,800,000 cells 24 leads identified received screened in 3 days in 23 days by evaluating from one of the 250,000 data po
Slide 10: ~400K patients treated with bamlanivimab
2020 BUSINESS UPDATE. COVID-19 PROGRAM ~400K PATIENTS TREATED WITH BAMLANIVIMAB alone and together 5,000+ patients across multiple clinical trials Bamlanivimab alone has been shown to: Reduce hospitalizations by 70% to 80% in patients recently diagnosed with mild to moderate COVID-19 Prevent COVID-1
Slide 11: Combat variants with bamlanivimab combinations
2020 BUSINESS UPDATE. COVID-19 PROGRAM COMBAT VARIANTS WITH BAMLANIVIMAB COMBINATIONS evaluated together with other antibodies emerging variants bamlanivimab + etesevimab bamlanivimab + VIR-7831 Reduces hospitalization & death by 87% Currently being evaluated in the BLAZE-4 in patients recently diag
Slide 12: Advancing a new, next-gen COVID-19 antibody
2020 BUSINESS UPDATE. COVID-19 PROGRAM ADVANCING A NEW, NEXT-GEN COVID-19 ANTIBODY. In late January, Eli Lilly moved a next-gen antibody discovered by AbCellera, 1404, into preclinical development. This antibody is: • Predicted to neutralize all circulating variant strains of COVID-19, including the
Slide 13: Acquisitions to expand the breadth & depth of our tech stack
2 0 20 B U S I NES S U PDAT E. T EC HNOLOGY EXPA NS ION ACQUISITIONS TO EXPAND THE BREADTH & DEPTH OF OUR TECH STACK Combine any two antibodies to Source fully human create bispecific antibodies. antibodies from rodents. OrthoMabTM bispecific Trianni next-generation mice are engineering platform, co
Slide 14: The goal: target to fill-finish in one year
2 0 20 B U S I NES S U PDAT E. T EC HNOLOGY EXPA NS ION THE GOAL: TARGET TO FILL-FINISH IN ONE YEAR. Abcellera Receives $126 Million from the Government of Canada to Future plans for deepening the tech stack include: Discover Solutions for COVID-19 and Build a Manufacturing Facility for Antibody Dru
Slide 15: Thank you Abcellerites & our families
THANK YOU ABCELLERITES & OUR FAMILIES
Slide 16: 2020 Financials Update
UPDATE 2020 FINANCIALS
Slide 17: Partnership business growth continued at a rapid pace through 2020
2 0 20 F U L L Y EA R F I N A NCIA L RES U LTS* PARTNERSHIP BUSINESS GROWTH CONTINUED AT A RAPID PACE + WITH downstream participation – WITHOUT downstream participation THROUGH 2020 5-year CAGR # of Cumulative # of Cumulative # of Discovery Partners Programs Under Contract Program Starts 27 103 52 +
Slide 18: $233.2M revenue driven by 71% increase in research fees & COVID-19 program
2 0 20 F U L L Y EA R F I N A NCIA L RES U LTS $233.2M REVENUE DRIVEN BY Year Total $233.2M 71% INCREASE IN RESEARCH FEES & COVID-19 PROGRAM $198.3M 20X Revenue USD ROYALTIES MILESTONES $15.0M $8.8M $11.6M +71% RESEARCH FEES $19.8M 2018 2019 2020
Slide 19: Operating expenses reflect continued strengthening of the platform
2 0 20 F U L L Y EA R F I N A NCIA L RES U LTS OPERATING EXPENSES REFLECT CONTINUED STRENGTHENING OF THE PLATFORM & NON-RECURRING COSTS Operating Expenses USD RESEARCH & DEVELOPMENT SALES & MARKETING GENERAL & ADMIN $29.4M $4.3M LCO $4.0M OrthoMab™ +$7.3M +$11M +$2.6M $11.9M $10.1M $1.9M Preferred $
Slide 20: Three other pre-tax income statement items increased by >$1 million
2 0 20 F U L L Y EA R F I N A NCIA L RES U LTS THREE OTHER PRE-TAX INCOME STATEMENT ITEMS INCREASED BY >$1 MILLION IN 2020 DEPRECIATION & AMORTIZATION INTEREST & OTHER EXPENSE GRANTS & INCENTIVES +$6.5M +$6.3M $8.3M +$3.2M $6.5M $4.8M $1.6M $1.8M $0.2M 2019 2020 2019 2020 2019 2020 • $2.5M due to am
Slide 21: Earnings jumped to $119M
2 0 20 F U L L Y EA R F I N A NCIA L RES U LTS EARNINGS JUMPED TO $119M: EQUIVALENT TO $0.53 (BASIC), $0.45 (DILUTED) PER SHARE Earnings USD NET EARNINGS (LOSS) EARNINGS PER SHARE: BASIC EARNINGS PER SHARE: DILUTED $118.9M $0.53 $0.45 ($2.2M) ($0.01) ($0.01) 2019 2020 2019 2020 2019 2020
Slide 22: Success in financing allowed for important investments in 2020
2 0 20 F U L L Y EA R F I N A NCIA L RES U LTS SUCCESS IN FINANCING ALLOWED FOR IMPORTANT INVESTMENTS IN 2020 & PROVIDES STRONG LIQUIDITY BEYOND Additionally, $198.3M accrued AR received subsequent to year end Cash Flows USD $683.7M IPO ($119.8M) $522.8M 3.8M Debt ($90.0M) $594.1M Repayment & Other
Slide 23: Thank you
ellera THANK YOU CELLERA